Surrey Heartlands

Joint Formulary & PAD

Degarelix - Prostate cancer

You are here : Home > Formulary Search > Degarelix - Prostate cancer

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Blue
Formulations :
  • Subcutaneous injection (sc)
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
BNF SPC
Restrictions / Comments :
Important

Initiation and 1st month supply by the specialist team before any request for primary care prescribing.

Documentation

Shared Care
Degarelix - Amber* information sheet - Jan 12

PAD Profile

ChemicalSubstance :
Degarelix
Indication :
Prostate cancer
Group Name :
Keywords :
Brand Names Include :
Firmagon
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
1

Other Indications

Below are listed other indications that Degarelix is used to treat.

  • No records returned.

Other Drugs

Below are listed other drugs that are used to treat Prostate cancer.

Committee Recommendations (1)

25 Jan 12 - Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
An Amber* Information sheet was sent to the tumour working group for comments and none were received. The PCN members noted that this would apply to small number of patients and concurred that the document should be approved and should circulated to the DTCs for discussion. The amber* information sheet is attached and will be uploaded again with contact details for each trust once it has been through their internal governance processes